Orchestra BioMed Holdings (OBIO) Cash & Current Investments (2020 - 2026)

Orchestra BioMed Holdings (OBIO) has 7 years of Cash & Current Investments data on file, last reported at $94.4 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 89.24% year-over-year to $94.4 million in Q1 2026; TTM through Mar 2026 was $94.4 million, a 89.24% increase from a year earlier, with the FY2025 full-year figure at $156.4 million, up 54.35% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $94.4 million, down from $156.4 million in the prior quarter.
• Over the last five years, Cash & Current Investments for OBIO reached as high as $215.9 million in Q2 2023 and fell as low as $735217.0 in Q3 2022.
• Historically, Cash & Current Investments has averaged $74.5 million across 5 years, with a median of $87.5 million in 2023.
• Across the five-year window, Cash & Current Investments jumped 16418.84% in 2023 and slumped 81.64% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $19.9 million in 2022, then surged by 340.5% to $87.5 million in 2023, then rose by 15.79% to $101.4 million in 2024, then surged by 54.35% to $156.4 million in 2025, then slumped by 39.65% to $94.4 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $94.4 million in Q1 2026, $156.4 million in Q4 2025, and $95.8 million in Q3 2025.